MARLBOROUGH, Mass.,
Sept. 9, 2020 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) announced it has received CE
Mark and initiated a limited market release of the fourth
generation Vercise Genus™ Deep Brain Stimulation (DBS) System
in Europe. Featuring full-body MRI
conditional1 and Bluetooth capabilities across the
portfolio, the Vercise Genus System is indicated to treat the
symptoms of Parkinson's disease (PD), essential tremor, and
dystonia by delivering precisely targeted electrical stimulation in
the brain designed to provide optimal symptom relief.
"With neurodegenerative movement disorders, the ability to
deliver the right dose of stimulation where it is needed can make a
remarkable difference in controlling an individual patient's
symptoms," says Veerle
Visser-Vandewalle, M.D., Ph.D., Cologne University Hospital,
Germany.
Vercise Genus adds features for patients, including a
low-profile two-in-one extension with the option of abdominal
placement. New clinician software optimizes programming with
integrated visualization using patient imaging via the company's
exclusive relationship with Brainlab.
"Advanced directional stimulation combined with a visualization
system based on a patient's own brain anatomy now provides the
accurate navigation as well as the steering capability we need to
optimize therapy outcomes," said Jens
Volkmann, M.D., Ph.D., director and chairman, Department of
Neurology at the University Hospital of Würzburg, Germany.
The fourth generation DBS system since 2012, Vercise Genus
builds upon rapid, meaningful innovations such as multiple
independent current control (MICC) and the Cartesia™ Directional
Lead with integrated visualization. "For patients, the Vercise
Genus DBS System continues the tradition of small, thin devices,
and it provides Bluetooth programming which is important during
times of social distancing," said Maulik
Nanavaty, senior vice president and president,
Neuromodulation, Boston Scientific. "Combined with the option of a
25-year rechargeable battery as well as the expanded MRI
conditional1 feature available on our primary cell
devices, patients can find the best option to suit their specific
needs."
More than 10 million people worldwide are living with PD – a
progressive, neurodegenerative disorder which causes stiffness,
slowness and tremors due to the decrease of dopamine in the
brain.2 Dystonia is the third most common movement
disorder after essential tremor and PD, affecting more than half a
million men, women, and children across Europe.3
In Europe, the Vercise Genus
DBS System is indicated for use in unilateral or bilateral
stimulation of the subthalamic nucleus or internal globus pallidus
for treatment of levodopa-responsive PD which is not adequately
controlled with medication and for treatment of intractable primary
and secondary Dystonia, for persons 7 years of age and older.
Thalamic stimulation using the Vercise Genus DBS System is
indicated for the suppression of tremor not adequately controlled
by medications in patients diagnosed with essential tremor or
PD.
The Vercise Genus DBS System is not available for use or sale in
the United States.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for 40 years, we advance science for life by providing a broad
range of high-performance solutions that address unmet patient
needs and reduce the cost of healthcare. For more information,
visit www.bostonscientific.com and connect
on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans and product performance and
impact. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list
and description of these and other important risks and
uncertainties that may affect our future operations, see Part I,
Item 1A – Risk Factors in our most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk
Factors in Quarterly Reports on Form 10-Q we have filed or
will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACTS:
Rainer Puster
Media Relations, Europe
+491754347057
Rainer.Puster@bsci.com
Rochelle Silsbee
Media Relations, U.S.
+1 (818) 812-7320 (office)
Rochelle.Silsbee@bsci.com
Susie Lisa, CFA
Investor Relations
+1 (508) 683-5565 (office)
BSXInvestorRelations@bsci.com
1 1.5 Tesla MRI conditional when all conditions
of use are met
2 https://www.epda.eu.com/about-parkinsons/what-is-parkinsons/
3 https://dystonia-europe.org/about-dystonia/dystonia
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-launches-vercise-genus-dbs-system-in-europe-301126978.html
SOURCE Boston Scientific Corporation